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Abstract
The cysteine protease legumain is involved in several biological and pathological processes, and the protease has been
found over-expressed and associated with an invasive and metastatic phenotype in a number of solid tumors.
Consequently, legumain has been proposed as a prognostic marker for certain cancers, and a potential therapeutic target.
Nevertheless, details on how legumain advances malignant progression along with regulation of its proteolytic activity are
unclear. In the present work, legumain expression was examined in colorectal cancer cell lines. Substantial differences in
amounts of pro- and active legumain forms, along with distinct intracellular distribution patterns, were observed in HCT116
and SW620 cells and corresponding subcutaneous xenografts. Legumain is thought to be located and processed towards its
active form primarily in the endo-lysosomes; however, the subcellular distribution remains largely unexplored. By analyzing
subcellular fractions, a proteolytically active form of legumain was found in the nucleus of both cell lines, in addition to the
canonical endo-lysosomal residency. In situ analyses of legumain expression and activity confirmed the endo-lysosomal and
nuclear localizations in cultured cells and, importantly, also in sections from xenografts and biopsies from colorectal cancer
patients. In the HCT116 and SW620 cell lines nuclear legumain was found to make up approximately 13% and 17% of the
total legumain, respectively. In similarity with previous studies on nuclear variants of related cysteine proteases, legumain
was shown to process histone H3.1. The discovery of nuclear localized legumain launches an entirely novel arena of
legumain biology and functions in cancer.
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Introduction
Legumain, or AEP (asparaginyl endopeptidase), belongs to the
cysteine protease family C13 in the clan CD according to the
MEROPS Peptidase Database [1]. It was first discovered in beans
[2] and blood fluke (Schistosoma mansoni) [3] before Chen and co-
workers described the mammalian version in 1997 [4]. The
mammalian protease is clearly homologous with legumain from
non-mammalian species and the conservation along the evolu-
tionary lineage presumably indicates functional importance. The
human pro-enzyme of 433 amino acids undergoes several
successive cleavages both N- and C-terminally, of which some
require acidic pH, before reaching the mature active enzyme
form. The maturation process is partially autocatalytic, but
depends also on other proteolytic enzymes which, along with the
complete understanding of the activation process, have not been
fully characterized [5–7]. The active protease shows highly specific
preference for substrate hydrolysis C-terminally to asparagine and
to some extent after aspartic acid under more acidic conditions.
The most potent endogenous inhibitors of legumain are cystatin
E/M and cystatin C [8,9], whereas the classic chemical inhibitor
of cysteine proteases, the compound E64, does not affect legumain
activity [4].
There are several reports of legumain being over-expressed in a
number of solid tumors (e.g. colorectal and breast cancers), and
this has also been correlated to a more invasive and metastatic
phenotype [10–12]. Recently, we screened a panel of melanoma
cell lines and found that legumain was expressed and active in
most of the cell lines investigated [13]. In normal tissues, legumain
is most prominently expressed in the placenta, kidney and spleen
[10]. Legumain knock-out mice are born healthy and fertile, but
display reduced body weight, aberrant endo-lysosomes with
development of kidney failure and extramedullary hematopoiesis
in the spleen [14–16].
Recently it has been shown that legumain may be involved in
cell proliferation independent of the endopeptidase activity [17].
Furthermore, legumain has been demonstrated to activate
proMMP-2, which may partially explain the observed association
between legumain expression and metastatic potential [18]. The
strict substrate specificity combined with over-expression in
various tumor types has motivated exploitation of legumain as a
pro-drug activator in cancer treatment, for instance by adding a
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cleavable peptide chain to doxorubicin or auristatin [10,19] and
targeting of drug compounds using a legumain enzyme inhibitor
[20]. Other known biological functions of legumain include
autophagic-lysosomal processing of hepatocellular proteins [21],
processing of antigens for MHC class II presentation [22], and
maturation in Toll-like receptor signaling [23].
In this study, legumain expression and proteolytic activity were
examined in two colorectal carcinoma (CRC) cell lines, HCT116
and SW620. Remarkable differences in activity were initially
identified and we further used these cell lines to examine legumain
distribution and activity at subcellular levels. Of great interest and
rather unanticipated, nuclear proteolytic active legumain was
revealed in both cell lines in addition to the expected endo-
lysosomal localization. These results were further acknowledged
by immunofluorescence, immunohistochemistry and in situ activity
measurements in cultivated cells and xenografts, and also
documented in human CRC tumor tissue. Finally, legumain was
shown to proteolytically cleave histone H3.1 in vitro unveiling a
potential functional implication of nuclear localized legumain
activity.
Materials and Methods
Cell lines, xenografts and CRC biopsies
RKO, CO205, SW48, Colo320DM, HT29, SW620 and
HCT116 were bought from American Type Culture Collection
(ATCC). KM20L2 and HCC2998 (DCTD Tumor/Cell Line
Repository) were kindly provided by Dr. Michael R. Boyd
(National Cancer Institute, Frederick, MD, USA), as well as
LS174T [24] and TC7 [25] cell lines from Dr. Richard Hamelin
(INSERM, Paris, France). Cell line identity was validated by short
tandem repeat analysis for the HCT116 and SW620 cell lines.
Cells were cultivated in RPMI 1640 (BioWhittaker) containing
10% fetal bovine serum (Hyclone), 20 mM Hepes (BioWittaker)
and 2 mM Glutamax (Invitrogen). All cell lines were routinely
tested negative for Mycoplasma. Subcutaneous xenografts from
HCT116 and SW620 were established by injection of 1*106 cells
in both flanks of locally bred female BALB/c nude (nu/nu) mice
[26]. Housing and all procedures involving animals were
performed according to protocols approved by the Oslo University
Hospital Animal Care and Use Committee, in compliance with
the Norwegian Animal Research Authority guidelines on animal
welfare. Human biopsies were obtained from patients during
primary surgery of assumed or verified CRC. The study was
approved by the Regional Ethics Committee of Southern Norway
(#S-98080) and written informed consent was obtained from the
patients.
Cell lysates, conditioned media harvesting and
subcellular enrichment
To obtain cell lysates for immunoblotting, sub-confluent
cultures were detached using EDTA (BioWittaker) and washed 3
times in ice cold PBS (BioWittaker) before cold lysis buffer
(150 mM NaCl, 50 mM Tris-HCl pH 7.5, 0.1% NP-40) with the
protease inhibitor mixture CompleteMini (Roche Diagnostics) was
added to dry cell pellets and left on ice for 15 min. Finally, the
samples were sonicated and centrifuged at 150006g for 15 min to
remove cell debris. In samples for activity measurements a lysis
buffer (100 mM sodium citrate, 1 mM disodium EDTA, 1% n-
octyl-beta-D-glucopyranoside, pH 5.8) without protease inhibitors
was used. Protein concentrations were determined using the BCA
(bicinchoninic acid) protein assay kit (Pierce) or Bradford assay
[27]. All samples were stored at 280uC. Conditioned cell medium
was acquired by seeding 7.5*105 cells in 6-well plates and grown
overnight in medium containing serum, then washed and grown
for another 24 hours in 1 ml serum-free medium. The serum-free
conditioned medium was centrifuged at 150006g for 5 min and
the supernatant collected. Proteins from the conditioned medium
were concentrated by addition of 4 volumes of ice cold acetone,
leaving the samples on ice for 15 min and centrifugation at 4uC
and 120006g for 10 min. Liquid was removed and the precipitate
air dried at room temperature before re-dissolving in buffers for
immunoblotting or activity measurements, according to subse-
quent protocols. Subcellular enrichment of lysosomes and nuclei
was performed by density gradient centrifugation according to
Brix et al. [28] with separation of the fractions repeated twice to
ensure high purity. Lysis buffers were adjusted to pH 5.0 and 7.4
for lysosomal and nuclear fractions, respectively. All other
subcellular enrichment was performed in triplicates using the
Subcellular Protein Fractionation Kit for Cultured Cells (Thermo
Scientific) on 5*106 HCT116 cells and 10*106 SW620 cells to
obtain equal volumes of cell pellets as starting material according
to the manufacturers’ protocol, and with the addition of washing
the pellet between all fractions to ensure high purity.
Immunoblotting and ELISA
Samples were run on NuPAGE gels 4–12% (Invitrogen) at
150 V and room temperature using the supplied MES-buffer
(containing SDS) according to the manufacturers’ protocol, and
then blotted onto 0.45 mm polyvinylidene fluoride (PVDF)
membranes (Millipore Corp.) in the X-cell Sure lock (Invitrogen)
at 4uC for one hour in 20% methanol containing Tris-Glycine
buffer. Quality of protein transfer was verified using Amidoblack
for 1D gels. The membranes were subsequently blocked for one
hour at room temperature in 5% dry milk TBST-buffer (Tris-
Buffered Saline with Tween 20) and probed with primary
antibody in 5% dry milk TBST-buffer for one hour at room
temperature at the following concentrations: legumain goat
polyclonal antibody (pAb) (1:1000; R&D Systems; AF2199),
cathepsin L goat pAb (1:500; R&D Systems; AF952), cathepsin
B rabbit pAb (1:10000; Calbiochem; 219408), cystatin E/M goat
pAb (1:500; R&D Systems; AF1286), a-tubulin mouse monoclonal
antibody (mAb) (1:5000; Calbiochem; CP06), arylsulfatase B
(ARSB) mouse mAb (1:500, R&D Systems; MAB4415), lysosomal-
associated membrane protein (lamp-2) mouse mAb (1:250, Santa
Cruz, sc-18822), specificity protein 1 (SP1) rabbit pAb (1:10000,
Millipore, 07-645), and histone H3 rabbit mAb (1:10000,
Millipore, 05-928). Then, the membranes were washed 3 times
in buffer without dry milk, probed with HRP-secondary (horse-
radish peroxidase) antibody (1:5000; DakoCytomatation) specific
against corresponding species for one hour at room temperature,
and subsequently washed 3 times. Development was performed
using SuperSignal West Dura Extended Duration Substrate
(Pierce) according to the manufacturers’ instructions, visualized
on medical X-ray films (Kodak or Thermo Scientific) and
converted to TIFF using a flatbed film scanner (Canon). For
densitometry analyses the film was scanned in a calibrated
densitometer GS-800 (Bio-Rad) and quantified by QuantityOne
v.4.6.5 (Bio-Rad). All measured quantities were normalized using
the corresponding loading control (a-tubulin). ELISA measure-
ments of human total legumain (R&D Systems, DY4769) from
three separate protein isolations were performed in duplicate
according to the manufacturers’ recommendations.
Mutation analyses
DNA from the cell lines HCT116 and SW620 was isolated
using the QIAamp DNA Blood Mini Kit (Qiagen). LGMN
(ENSG00000100600) exon 12 (ENSE00000808693) was subse-
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quently generated by PCR using specific forward (59-agaggctg-
gacttggggtat-39) and reverse (59-gcttccgttacatggaggac-39) primers.
Sequencing reactions were performed using the same primers and
the Dyenamic ET Dye Terminator Cycle Sequencing Kit
(Amersham) as described by the supplier. The samples were
finally subjected to post clean up, separated by capillary
electrophoresis and analyzed using a MegaBACE1000 sequencing
instrument (Amersham).
Legumain activity, immunofluorescence and
immunohistochemistry
Legumain activity in cell lysates and subcellular fractions was
measured in triplicate by cleavage of the substrate Z-Ala-Ala-Asn-
NHMec (Department of Biochemistry, University of Cambridge,
UK) as previously described [4,29]. In brief, cell lysate (20 ml) was
added to black 96-well microplates (No. 3915; Costar, Corning).
After the addition of 100 ml buffer and 50 ml substrate solution
(final concentration 10 mM) at either pH 5.8 or 7.4, a kinetic
measurement based on increase in fluorescence over 10 min was
performed at 30uC in a plate reader (Wallac Victor 3,
PerkinElmer) and presented as enzyme units where one unit of
activity was defined as the amount of enzyme releasing 1.0 mmol
of product/min under the standard conditions described. Immu-
nofluorescence was performed on cells grown on sterilized glass
slides in 6-well plates subsequently fixed in 4% PFA and
permeabilized with 0.2% Triton-X100 before staining with
legumain primary antibody (1:100) and a secondary antibody
conjugated with Alexa488 (Invitrogen, 1:200, A-11034) in buffer
containing 0.1% BSA. Control slides were prepared without
addition of primary antibody. Nuclei were stained with
DRAQ5TM (Biostatus) and coverslips mounted in Mowiol in
200 mM Tris-HCl, pH 8.5 (Hoechst) before observation on laser-
scanning confocal imaging system LSM510 or LSM710 (Carl
Zeiss). Image arithmetics were performed according to Jedeszko et
al. [30] using Image J [31]. The analysis of nuclear localized
legumain was performed on 5 z-stacks each composed of 25–35
sections and each containing 30–40 cells captured without
saturated pixels.
In situ activity of legumain in cells and tissue sections from
xenografts was measured by cleavage of the substrate Suc-Ala-Ala-
Asn-NHNapOME (Department of Biochemistry, University of
Cambridge, UK) as previously described and verified on tissue
from legumain knock-out mice [32,33] using final concentrations
of 1 mM 5-nitro-salicylaldehyde, 0.5 mM substrate and supplied
with DAPI (Invitrogen) to visualize nuclei. Cells mounted in OCT
Compound (Tissue-Tek) and xenografts were cut into cryostat
sections (6 mm) and incubated with 50 ml assay solution for 10–
15 min at 37uC before observation by means of laser-scanning
confocal imaging system LSM710 or LSM510, respectively, and
using the co-localization module of the Zen 2009 software for
pseudo-coloring (white). Control slides were prepared using buffer
without substrate, the epoxy inhibitor E64 (Sigma) at a final
concentration of 1 mM or human recombinant cystatin E/M
(R&D Systems, 1286-PI) at a final concentration of 0.1 mM.
Immunohistochemical staining was performed on formalin-fixed,
paraffin-embedded tissue sections from subcutaneously grown
xenografts and human CRC biopsies, using the legumain antibody
at 1:300 dilution with the biotin-streptavidin-peroxidase method as
described previously [34]. Goat-IgG isotype control stainings were
performed at similar concentration on xenograft and CRC tumor
tissue sections.
Proteolytic cleavage of histone H3.1
Human recombinant legumain (R&D systems, 2199-CY) was
auto-activated at 37uC for 2 h in acidic buffer (50 mM NaOAc,
100 mM NaCl, pH 4.0) at concentration 0.1 mg/ml. Bovine
legumain was isolated from kidney as described by Yamane et al.
[35]. Human recombinant histone H3.1 (New England BioLabs,
M2503S) was added to 50 ml assay buffer (50 mM MES, 250 mM
NaCl, pH 5.0 or pH 7.0) with or without cystatin E/M and with
final addition of either active human or bovine legumain. Each
mixture was incubated at 37uC for 2 h with shaking.
Results
Legumain and cathepsin L are heterogeneously
expressed in CRC cell lines
Lysates from a panel of CRC cell lines were subjected to
separation by PAGE and blotted onto PVDF membranes. By
successive probing with polyclonal antibodies, the total amount
and various mature forms of legumain (upper panel, Fig. 1 and
Fig. S2A) and cathepsin L (middle panel, Fig. 1 and bottom panel,
Fig. S2A) were visualized. Legumain appeared to be present in two
molecular mass forms of approximately 56 and 36 kDa (arrows).
The CRC cell lines displayed a wide range in the total amount of
legumain, and also in relative amounts of the putative pro-form of
56 kDa and the active mature form of 36 kDa, which both were
sensitive to down-regulation by a legumain specific siRNA (Fig.
S1). Recombinant human pro-legumain (rhLeg, 5 ng) was used as
control. Cathepsin L was present in most cell lines although the
highest levels were seen in RKO, TC7 and HCT116. In the two
latter, which harbor high amounts of mature legumain, the most
dominant cathepsin L band corresponded to the 25 kDa heavy
chain of the two-chain active form (arrow). In contrast, the RKO
cell line showed simultaneous high expression of inactive (30 kDa,
single chain) cathepsin L and a lower level of active legumain,
suggesting that these cysteine proteases are subjected to mutual
activation in colorectal cancer cell lines.
The cell lines HCT116 and SW620 show divergent
legumain activity
HCT116 cells predominantly displayed the mature 36 kDa
form of legumain, whereas SW620 also showed substantial
amounts of the 56 kDa pro-form (Fig. 1 and TL; Fig. 2B) [6].
Lysates from these two cell lines were further analyzed for their
capability to cleave a legumain specific substrate. These activity
measurements revealed a consistent correspondence between the
observed intensity of the 36 kDa band and legumain activity in
total lysates (TL; Fig. 3B). Furthermore, HCT116 and SW620
cells treated with a siRNA specific for legumain demonstrated a
70–90% decrease in legumain activity (data not shown). Having
established evidence for the differences in amount of active
legumain in HCT116 and SW620 it was of interest to determine
whether this could be attributed to mutations in Asn323 located in
exon 12, which has been claimed necessary for cleavage of the pro-
enzyme into the active form [5,6,36]. However, sequencing
showed no mutations in the LGMN nucleotide sequence corre-
sponding to the cleavage recognition site in these cell lines (data
not shown), and could thus not explain the observed difference in
protease activity. Furthermore, cystatin E/M has been shown as
the most potent endogenous inhibitor of legumain and expression
of this protein was therefore investigated. Interestingly, the cellular
and secreted levels of cystatin E/M were found to be quite
different between the two cell lines. In HCT116, two forms (14
and 17 kDa) of cystatin E/M were found in conditioned media
(CM; Fig. 2B), with more modest amount and mainly the 14 kDa
Nuclear Localization of Active Legumain
PLOS ONE | www.plosone.org 3 January 2013 | Volume 8 | Issue 1 | e52980
form in the total cell lysate (TL). In contrast, SW620 expressed no
detectable amounts of cystatin E/M neither secreted nor
intracellular.
Active legumain is localized to the endo-lysosomal and
nuclear compartments
Legumain is usually considered a protein targeted to and
residing in endo-lysosomes, and it has also been reported to
execute important cellular functions inside this specialized
compartment [22], while its distribution and characteristics in
other subcellular compartments has not been elucidated. To
further investigate this we used two methods to isolate and enrich
proteins from subcellular compartments, one being based on
density gradient centrifugation in sucrose buffer and the other
being a commercially available subcellular isolation kit. To
examine the distribution of legumain, immunoblotting was
performed on 15 mg total protein lysate from each enriched
subcellular fraction, in addition to total cell lysate and corre-
sponding conditioned growth medium (Fig. 2). This also enabled
for purity control of the fractions using various proteins of
presumed limited distribution, showing high enrichment of each
compartment and with almost no detectable cross contamination
(Fig. 2, compartment-specific markers displayed below black lines).
In both subcellular enrichment methods the 36 kDa active
legumain was present in substantial amounts in the lysosomal (L)
and membrane/lysosomal (M/L) fractions, as well as in the
nuclear (N) and nuclear soluble (NS) fractions in both both cell
lines. It was again perceived that overall HCT116 compared to
SW620 cells contained a lower level of the 56 kDa pro-form in all
subcellular fractions, confirming the observations made from total
cell lysates (Fig. 1 and 2), while the 56 kDa prolegumain was also
observed in the nuclear fractions in both cell lines. HCT116 cells
also displayed smaller amounts of 36 kDa legumain in the
cytosolic (C) and nuclear chromatin bound (NC) fractions
(Fig. 2B and Fig. S2C, left middle panels). The 56 kDa pro-form
of legumain was found to be secreted and detected in conditioned
media (CM; Fig. 2B), but only from HCT116. Of particular
interest was the clear presence of the 36 kDa active legumain in
the nuclear fractions from both cell lines, in addition to the
anticipated presence in the lysosomal fractions. Additionally,
subcellular enrichment was performed using a second commer-
cially available subcellular isolation kit (Qiagen), also demonstrat-
ing the nuclear localization of mature 36 kDa legumain (Fig. S2B).
Regarding the endogenously expressed inhibitor cystatin E/M,
only trace amounts of the 14 kDa form was observed in both the
M/L and NS fraction of HCT116. Finally, subcellular distribution
of cathepsin L was also evaluated and this protease was found to
be much less prominent in SW620 compared to HCT116 cells
(Fig. 2B and Fig. S2C, lower panels), as was also apparent in total
cell lysates (Fig. 1 and 2B). In HCT116 the presumed 25 kDa
active two-chain form of cathepsin L [37] was clearly present in
the M/L and NS fractions as well as in TL and CM, but also to
some extent in the C and NC fractions. Although present in active
form in the CM, this fraction also showed the pro-form of
cathepsin L viewed by a strong band of approximately 38 kDa.
The cathepsin L single-chain form of 30 kDa was mainly present
in the M/L and NS fractions of both cell lines. In SW620, weaker
bands of cathepsin L were observed only in the M/L and NS
fractions as well as in TL, and also with a faint presence of the pro-
form in CM.
The various subcellular fractions from HCT116 and SW620
cells were subsequently analyzed for their capability to proteolyt-
ically cleave a legumain specific peptide substrate relative to the
total amount of proteins present in each measured fraction. In
lysosomal and nuclear fractions separated by sucrose density
gradients, the activity was measured at both pH 5.8 and 7.4,
respectively, to mimic physiological conditions (Fig. 3A). In
conjunction with previous studies, the lysosomal fractions demon-
strated high proteolytic legumain activity, but more unanticipated
the nuclear fractions of both cell lines measured at neutral pH also
Figure 1. Expression of legumain and cathepsin L in CRC cell lines. Immunoblots of cell lysates from a panel of CRC cell lines demonstrated
high variability in the total amount of legumain and cathepsin L, and also in the presence of the different mature forms. HCT116 and SW620 cells
were particularly interesting as they show mutually exclusive high amount of the active (36 kDa) and inactive pro-form (56 kDa) of legumain,
respectively. Uncut immunoblots (Fig. S2A).
doi:10.1371/journal.pone.0052980.g001
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showed considerable legumain activity. In the subcellular fractions
isolated using the commercial kit, proteolytic activity of legumain
measured at pH 5.8 was also highest in the M/L (Fig. 3B) fraction,
however, in correspondence with previous results, substantial
legumain activity was found in the nuclear fractions of both cell
lines, in particular the soluble fractions (NS). Furthermore,
legumain expression in the subcellular fractions obtained by using
the commercial kit was assessed using sandwich ELISA capable of
detecting total legumain (i.e. both pro- and active forms) (Fig. 3C).
In all fractions detectable amounts of legumain (relative to total
protein content in each fraction) were observed, while the highest
levels were observed in the M/L and NS fractions, as also seen on
the immunoblots (Fig. 2B). An unanticipated result was the
quantity and activity of legumain in the subcellular fractions from
10*106 SW620 cells which were measured to be approximately
twice as high as in fractions made from 5*106 HCT116 cells,
although all lanes were loaded with 15 mg protein. However, in
total lysates the entire amount of legumain (pro- and mature-form)
was nearly equal, yet HCT116 cells had higher overall legumain
activity in the total cell lysates which corresponds to the observed
amount of active legumain in the immunoblots (Fig. 2B).
In situ distribution of legumain expression
To examine legumain expression in situ, HCT116 and SW620
cells were cultured on glass slides, immunofluorescently stained
and visualized using confocal microscopy (Fig. 4A–4D and Fig.
S3A–S3B). Legumain was mainly distributed in the perinuclear
region, possibly suggesting majorly localization to the trans-Golgi
network (TGN) and endo-lysosomes, and most clearly visible in
the HCT116 cells (Fig. 4A), whereas in the SW620 cells legumain-
Figure 2. Legumain, cystatin E/M and cathepsin L expressions in subcellular fractions of HCT116 and SW620 cells. (A) Immunoblots of
legumain in lysosomal (L) and nuclear (N) fractions enriched from HCT116 and SW620 cells using density gradient centrifugation. All lanes were
loaded with 15 mg total protein from each fraction. Purity controls of the subcellular fractions were assessed by staining for ARSB (soluble lysosomal
protein) and SP1 (nuclear transcription factor). (B) Immunoblots of legumain (top panels), cystatin E/M (second panels) and cathepsin L (third panels)
in enriched subcellular compartments isolated from HCT116 and SW620 cells using a commercial kit: Cytosol (C), membranes/lysosomes (M/L),
nuclear soluble (NS), nuclear chromatin bound (NC), total lysate (TL) and conditioned media (CM). All lanes were loaded with 15 mg total protein from
each fraction, except conditioned media where proteins precipitated from 1 ml was loaded. Purity controls of the different subcellular fractions were
assessed by staining for a-tubulin (cytosolic protein), ARSB (soluble lysosomal protein), lamp-2 (lysosome membrane-associated protein), SP1 (nuclear
transcription factor) and histone H3 (nuclear chromatin bound protein). Uncut immunoblots of legumain and cathepsin L (Fig. S2C).
doi:10.1371/journal.pone.0052980.g002
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containing vesicles appeared more distributed (Fig. 4C). Both
HCT116 and SW620 also displayed legumain located in the
nuclei of the cells. By visualizing only the nuclear localized
legumain in all three orthogonal planes of the cells, legumain was
observed to distribute around spherical structures, possibly
nucleoli, inside the nuclei (Fig. 4B and 4D). Using image
arithmetics on optical slices from five independent z-stacks, each
containing 30–40 immunofluorescently labeled cells, the average
percentage of intracellular legumain localized in the nucleus of a
cell was estimated to 12.8% in HCT116 and 16.5% in SW620
(Fig. 5). Additional analysis of the two cell lines grown as
subcutaneous xenografts in mice revealed comparable results to
immunofluorescence labeling when immunohistochemically
stained for legumain (Fig. 4E and 4F, and Fig. S3C–S3F), with
HCT116 showing intense granulated staining whereas SW620
demonstrated a much more diffuse staining pattern. Furthermore,
in xenografts from both cell lines legumain exhibited heterogenous
expression, with intensely stained areas, possibly necrotic tissue.
Nuclear localization was most visible in cells with overall high
legumain expression, but spots of legumain staining were also
detected inside nuclei in the weaker stained cells (yellow arrows).
Immunohistochemical analysis of paraffin embedded tumor tissue
from CRC patients, also revealed heterogeneous expression of
legumain which was apparent both in the tumor cells and the
surrounding stromal cells (Fig. 4G and Fig. S3G). Most strikingly
are the intensely stained nuclei present in about 50% of the tumor
cells and 30% of the stromal cells (yellow and green arrow,
respectively), whereas other adjacent cells demonstrated no
nuclear staining. Furthermore, the overall staining pattern showed
elevated cytoplasmic presence of legumain in all apparent
carcinoma cells compared to the stromal cells (red and blue
arrow, respectively).
In situ distribution of legumain activity
Having established nuclear expression of legumain in situ, it was
of interest to see whether proteolytic activity also could be verified
in this compartment of intact cells. Performance and specificity of
a legumain specific substrate was verified on non-fixed cryosec-
tions from xenografts by incubation with or without the substrate
(Fig. 6A, upper pictures and Fig. S3J) demonstrating the presence
of active legumain, while addition of the E64 cathepsin inhibitor
did not appear to affect the cleavage of the substrate (Fig. 6A,
lower left picture and Fig. S3J). In contrast, incubation with
recombinant cystatin E/M completely abolished detectable
legumain activity (Fig. 6A, lower right picture and Fig. S3J),
altogether confirming the legumain specificity of the chosen
substrate at the established conditions. This substrate was further
used to analyze in situ legumain activity on cryosections from
HCT116 cells (Fig. 6B) and xenografts from both cell lines (Fig. 6C
and 6D). In HCT116 cells, legumain activity in the cytoplasm
appeared diffuse, but also with more bright and distinct spots
(Fig. 6B, middle, gray arrow). In addition, activity was observed as
distinct spots (right, yellow arrow) in the cell nucleus viewed by co-
localization (white). On cryosections made from xenografts
established from HCT116 cells, legumain activity in the cell
nucleus (Fig. 6C, yellow arrow) was less strong and distinct,
whereas small intense vesicles could be observed in the cytoplasm
(gray arrow) together with more diffuse (blue arrow) activity.
Parallel analysis of xenografts made from SW620 cells showed less
distinct activity in the cytoplasm (Fig. 6D, blue arrow), but was
quite focused in the nucleus (yellow arrow). Altogether, the
observations on legumain expression and activity in situ confirmed
the findings by immunoblotting and activity measurements of
subcellular fractions, and further revealed differences between
HCT116 and SW620 cells in legumain distribution. Nonetheless,
both cell lines showed presence of active legumain in the nucleus.
Figure 3. Proteolytic activity and quantity of legumain in
subcellular fractions of HCT116 and SW620 cells. (A) Proteolytic
activity of legumain determined by substrate cleavage (Z-Ala-Ala-Asn-
NHMec) relative to total protein content of each subcellular compart-
ment of HCT116 (dotted bars) and SW620 (chequered bars) cells after
density gradient centrifugations. Lysosomal and nuclear fractions were
prepared and analyzed at pH 5.8 and 7.4, respectively, demonstrating
proteolytic activity of legumain in both lysosomal and nuclear fractions
of both cell lines at both pH conditions, although highest in the
lysosomal compartment assayed at pH 5.8. (B) Proteolytic activity of
legumain measured at pH 5.8 in subcellular fractions prepared by a
commercial kit was found to be highest in the M/L fractions, but was
also clearly present in the NS fractions and observed with only minor
activity in the C fractions of both cell lines. Extracellular legumain did
not demonstrate any activity in either cell line (data not shown). (C)
Total legumain amounts (pro- and active form) measured by ELISA in
subcellular fractions (isolated using a commercial kit) and calculated
relative to the total protein content in each fraction were also highest in
the M/L fractions, yet clearly present in the NS fraction.
doi:10.1371/journal.pone.0052980.g003
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Figure 4. Subcellular localization of legumain in HCT116 and SW620 cells, subcutaneous xenografts, and human CRC tumor tissue.
(A to D) Immunofluorescence staining of legumain (green and top left panels) and nuclei (red and middle left panels) in HCT116 (A) and SW620 (C)
cells cultured on glass slides and visualized as orthogonal slices of z-stacks by confocal laser scanning microscopy. By using image arithmetics with
the binarized capture of corresponding DRAQ5TM-positive nuclei as a mask, nuclear legumain representative signals were extracted from all optical
sections and visualized in grayscale as orthogonal slices for HCT116 (B) and SW620 (D). Scale bars represent 10 mm. Specificity of immunofluorescence
signals was verified by incubation with secondary antibodies only, yielding no signal (Fig. S3A and S3B). (E and F) When grown as subcutaneous
xenografts in mice, immunohistochemical staining of legumain in HCT116 (E) cells demonstrated a much more granulated staining pattern than in
SW620 (F) cells. However, both cell lines exhibited areas of strong legumain expression and also in the nuclei (yellow arrows). Scale bars represent 50
(top panels) and 25 (bottom panels) mm. H/E stain (Fig. S3C and S3D). Goat-IgG isotype control showed low staining (Fig. S3E and S3F). (G)
Immunohistochemical staining of legumain in paraffin-embedded section from a representative CRC tumor biopsy showing nuclear staining of
legumain in some, but not all, epithelial cells (i.e. carcinoma cells; yellow arrow) and stromal cells (green arrow). Epithelial cells also exhibited marked
granulated staining in the cytoplasm (red arrow), whereas stromal cells showed much weaker staining outside the nucleus (blue arrow). Scale bar
represent 50 mm. Goat-IgG isotype control showed no staining (Fig. S3G).
doi:10.1371/journal.pone.0052980.g004
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Histone H3.1 is proteolytically cleaved by legumain
Given the presence of active legumain in the nucleus and in line
with a previous report on cathepsin L [38] it was of interest to
investigate whether legumain was able to cleave the nuclear
protein histone H3. By the use of auto-activated human
recombinant legumain produced in mammalian cells, it was
demonstrated that incubation at pH 5.0 resulted in a dose
dependent proteolytic cleavage of recombinant histone H3.1
(Fig. 7A and Fig. S2D, lanes 6–8), which was nearly abolished in
presence of cystatin E/M (Fig. 7A and Fig. S2D, lane 9). The auto-
activation of legumain only produced the intermediate 46 kDa
form of the protease, hence not the endogenously observed and
presumably fully matured 36 kDa form. We therefore repeated the
experiment using fully matured legumain purified from bovine
kidney, and detected an even higher proteolytic activity resulting
in near complete cleavage of histone H3.1, including the
appearance of an approximately 12 kDa cleavage product which
Figure 5. Percentage of expressed legumain located in the nucleus. (A and B) Representative pictures of HCT116 (A) and SW620 (B) cells by
one optical slice from one of five independent z-stacks each containing 30–40 immunofluorescently labeled cells using legumain-specific antibodies
(green), with DRAQ5TM counter-stained nuclei (binarized; white). By means of a semi-automated procedure in Image J the captures of nuclei
(binarized) was used as a mask to separate the nuclear (top right) from the cytoplasmic (top middle) signal components of the total (top left) signal
representing expression of legumain. The total signal from legumain fluorescence in each optical slice was summarized from all five z-stacks enabling
for the estimation of the expressed amount of legumain in the nuclear compartment. Statistical errors in the calculations are reported as standard
error of the mean of the five independent z-stacks. Scale bar represents 20 mm.
doi:10.1371/journal.pone.0052980.g005
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apparently also was a substrate for further legumain processing
(Fig. 7A and Fig. S2D, lanes 1–3). Addition of cystatin E/M
completely blocked cleavage of histone H3.1 by bovine legumain
(Fig. 7A and Fig. S2D, lane 4). The experiment was also
conducted under pH conditions adjusted to 7.0, which resulted
in appearance of the 12 kDa histone H3.1 cleavage product in a
dose dependent manner using the fully matured 36 kDa legumain,
which was blocked by cystatin E/M (Fig. 7B, lane 1–4). The
proteolytic cleavage rate for fully matured legumain was appar-
ently much slower at neutral than at acidic pH, as most of the
intact histone was observed. The 46 kDa intermediate active form
of legumain did not result in any cleavage products at neutral pH
(not shown).
Discussion
In consistence with previous reports [10,39], legumain and
cathepsin L were found ubiquitously expressed in a panel of CRC
cell lines. However, clear variations in protease amounts and ratios
between the various maturation forms of each protease were
identified. Both legumain and cathepsin L require a multistep
Figure 6. In situ legumain activity in cultured cells and
subcutaneous xenografts. (A) In situ proteolytic activity (green)
captured by fluorescence microscopy imaging of adjacent cryosections
from a HCT116 subcutaneous xenograft incubated with (top left) and
without (top right) legumain substrate, legumain substrate and E64
(lower left) or legumain substrate and recombinant cystatin E/M (lower
right), demonstrating the specificity of the synthetic peptide Suc-Ala-
Ala-Asn-NHNapOME utilized as legumain substrate. All pictures were
taken using true colors, after the same incubation time and with
identical microscope and camera settings. Scale bar represents 100 mm.
Subcutaneous xenografts with SW620 cells (Fig. S3J). (B) Subcellular
localization of active legumain (green) in HCT116 cells (made from
cryosections after mounting in OCT-medium) with nuclei stained by
DAPI (red) and analyzed by confocal laser scanning microscopy. This
showed granulated activity inside (yellow arrow) and outside (gray
arrow) of the nucleus. Localization in the nucleus was confirmed by co-
localization (white) of legumain activity and the nuclear counter-stain
(right panel). Scale bar represents 10 mm. HCT116 cells incubated
without substrate, or with substrate and cystatin E/M, showed no
signals (Fig. S3H and I, respectively). (C and D) Legumain activity (green)
in cryosections from subcutaneous xenografts with nuclei stained with
DAPI (red) and analyzed by confocal laser scanning microscopy.
Subcutaneous xenograft from HCT116 cells (C) showed similar results
as in cultured cells with intense granulated activity (gray arrow)
although less distinct activity in the cytoplasm (blue arrow) and within
the nucleus (yellow arrow) was also observed. However, in the
subcutaneous xenograft of SW620 cells (D) majorly diffuse legumain
activity was observed in the cell cytoplasm (blue arrow), while in the
nucleus this was more concentrated (yellow arrow). Scale bars represent
50 mm.
doi:10.1371/journal.pone.0052980.g006
Figure 7. Cleavage of histone H3.1 by active legumain. (A)
Immunoblots showing the cleavage of intact (lane 10) recombinant
human histone H3.1 in a dose dependent manner by purified mature
36 kDa bovine legumain (bovLeg, lane 1–3) and auto-activated
intermediate form (46 kDa) of recombinant human legumain (rhLeg,
lane 6–8). The addition of recombinant human cystatin E/M (lane 4 and
8) efficiently blocked legumain activity and resulted in almost complete
rescue of histone H3.1 from proteolytic cleavage. Uncut immunoblots
(Fig. S2D). (B) Immunoblot of histone H3.1 showing the dose-
dependent production of a 12 kDa cleavage product after incubation
of recombinant histone H3.1 with fully mature 36 kDa bovine legumain
in a buffer with pH 7.0 (lane 1–3). Addition of recombinant human
cystatin E/M efficiently blocked legumain activity and resulted in
virtually no formation of the 12 kDa cleavage product (lane 4).
doi:10.1371/journal.pone.0052980.g007
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activation process to reach their mature forms. These maturation
processes are not completely elucidated, but both autocatalytic
activity and an interplay between the various cysteine proteases
have been suggested [6,7,40]. However, based on the presented
immunoblots no statistically significant co-variation in the
expression levels of the analyzed proteases was observed, nor
was it possible to decipher any consistency in the total amount of
the presumed active forms. This could be ascribed to the
complexity of the maturation process in which these two cysteine
proteases represent only some of all proteases involved. Further-
more, influences caused by variations in experimental conditions
like pH and cell density could add to the complexity in the
interpretation of the results.
The difference in relative amounts of the 56 and 36 kDa
legumain forms, representing the zymogen and the mature active
protease, respectively [4,6,13], was most prominent between the
cell lines HCT116 and SW620. Several explanations for the
observed differences in legumain processing, and thus proteolytic
activity, could be postulated. Initially, exon 12 in the LGMN gene,
harboring a presumed crucial target for processing to the active
36 kDa form, was sequenced without revealing any mutations that
could explain the lower level of mature legumain in SW620.
Secondly, insufficient buffering capacity of the cultivating medium
could possibly influence intracellular functions. However, mea-
surements of pH prior to cell harvesting did not reveal differences
in the experimental conditions between the cultures of both cell
lines (data not shown). Furthermore, the legumain inhibitor
cystatin E/M was found in HCT116, but not in the SW620 cell
line. In line with the original reports [41,42] we also found two
molecular mass forms of cystatin E/M. The 17 kDa was mainly
secreted whereas the 14 kDa form was both secreted and
dominant in lysates from HCT116 cells. Previously, we have
reported an inverse correlation between secreted 17 kDa cystatin
E/M and active legumain in melanoma cells [13]. Cystatin E/M is
supposed to inhibit proteolytic activity of mature legumain, and
although part of the maturation process is autocatalytic there are
no indications that the inhibitor per se restrains processing towards
active protease [40], possibly as a consequence of physical
separation of the two proteins during the maturation process
[43]. Therefore, discrepancy in cystatin E/M expression can
probably not explain the observed differences in mature 36 kDa
legumain between the two colon cancer cell lines. Finally, addition
of ammonium chloride in the growth media to increase lysosomal
pH and inhibit legumain maturation [36], did remove all
detectable 36 kDa legumain (data not shown). Thus, lysosomal
maturation seems to be primarily responsible for the appearance
of the active form, and speculations can be made to whether
aberrant lysosomal transport or function could explain low activity
in SW620. This hypothesis is in concurrence with our observations
from immunohistochemistry and in situ activity measurements on
subcutaneous xenografts showing a more granulated localization
of legumain expression and activity in HCT116 than in SW620
cells. Furthermore, immunofluorescence imaging demonstrated
that legumain is more distributed throughout the entire cell in
SW620 compared to the main presumed TGN and lysosomal
location in HCT116 cells.
The dominant theory for intracellular transport of legumain is
through the TGN and further into lysosomes via late endosomes,
where trimming by autocatalysis and other proteases takes place
[7,40]. Anyhow, cysteine proteases are also known to be subject to
alternative trafficking in the cells [44]. In line with other studies
[45], the highest amounts of legumain were observed in the intra-
organelle membrane fraction (Golgi, endosomes, lysosomes), but
substantial amounts of legumain were surprisingly also found in
the cell nucleus. The amount of legumain relative to the total
protein content in each compartment differs from the amount
compared to total cellular protein, possibly explaining why more
active legumain was observed in the subcellular compartments of
the SW620 cell line than in the total cell lysate. Another
explanation could be that some of the pro-form is cleaved during
experimentation giving rise to the mature active form. The ratio
between pro- and active form in the lysosomal fractions of
HCT116 is in concurrence with the observed ratio in total cell
lysate, and suggests rapid processing to the mature 36 kDa form
within the lysosomes/membrane structures. Although higher
amounts of active legumain were observed in the M/L fraction
of SW620 cells than in the total lysate, the substantial presence of
pro-legumain in the M/L fraction suggests that even though
legumain is transported to the endo-lysosomes, its processing is not
as efficient in SW620 as in HCT116 cells. In line with a previous
report [6], only the pro-form was detected extracellularly, and
interestingly only from the HCT116 cell line, although SW620
demonstrated high levels of this form intracellularly. This was also
reflected by the total absence of legumain activity in conditioned
media (data not shown), and suggests that the protease either does
not mature or is unstable in its active form under the culturing
conditions used. Legumain activity has, however, recently been
reported in conditioned media from other cell lines [19],
suggesting that certain growth conditions (e.g. hypoxia often
encountered in tumors) would be more favorable towards protease
maturation, and furthermore, that the active form of legumain
may be stabilized by certain co-factors [5]. This newly proposed
theory of stabilizing co-factors may also explain how legumain
could be active in the nuclear compartment which presumably
does not have the optimal pH, which was observed for the nuclear
fractions showing considerable proteolytic activity at pH 7.4. One
candidate could be histones, also demonstrated as a potential
substrate in this study, alone or in complex with DNA, previously
revealed to act as a template for cysteine cathepsin interaction with
endogenous protease inhibitors that serve as substrates [46].
Legumain expression and activity was observed in the nucleus of
both CRC cell lines analyzed in this study. This novel finding was
first demonstrated by immunoblotting, ELISA and proteolytic
activity measurements, and further confirmed by immunofluores-
cence and detection of enzymatic activity in situ on both intact cells
and xenografts in addition to immunohistochemistry on tissue
from xenografts and on human CRC tumor tissue. Yet, the
cellular route taken by legumain to reach the nucleus appears
enigmatic, with both the pro- and active forms observed in this
subcellular compartment. Analysis of the legumain amino acid
sequence with a nuclear localization signal (NLS) prediction
algorithm [47] returned two potential NLSs in the C-terminal
region with a score suggesting strong, but not exclusive,
localization to the nucleus (Fig. S4). Interestingly, the predicted
mono- and bipartite NLS signal are located on each side of the
predicted maturation site at N323, which could be of importance
in favoring nuclear import before or after maturation of legumain.
In support of the hypothesis that maturation cleavage takes place
before nuclear import, was our finding of low expression of
prolegumain in the nuclear fractions of HCT116 and SW620 cells,
but this is a topic that needs further exploration. For future studies,
although not within the scope of this report, it seems vital to
explore the proteolytic network of either cell line in a more
comprehensive approach since also amounts and differential
localization patterns of e.g. cysteine cathepsins may add to the
extent of prolegumain processing including unmasking of nuclear
targeting sequences.
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Although acidic pH has been reported as optimal for activity
and stability of legumain [4–6], proteolytic activity of the nuclear
fractions at neutral pH was observed. Furthermore, cleavage of
histone H3.1 at pH 7.0, which is close to presumed physiological
pH in the nucleus, was also seen. The activity was less prominent
than at pH 5.0, but as previously mentioned, certain co-factors
may stabilize the mature form and promote the proteolytic activity
at neutral pH [5]. In addition, proteolytic activity at neutral pH
has been reported for cathepsins [48] and legumain in Blastocystis
[49]. In line with previous reports, the in situ activity measurements
on cells and tissue demonstrate that the most prominent legumain
activity was observed as granulated spots in the cytoplasm of
HCT116 cells, probably representing the endo-lysosomes. These
vesicles have high levels of legumain and optimal pH for activity,
and are thus regarded as the canonical location for legumain
activity. As the percentage of nuclear localized legumain was
demonstrated to be only minor and not exceeded 17% of the total
detectable legumain, such vesicles might therefore in previous
studies have masked less prominent locations like the nucleus. For
certain biological processes high substrate cleavage rate is essential,
but for others the processing of a given protein even at a slower
rate may be very important.
To our knowledge, legumain expression and activity have not
previously been examined in the cell nucleus, while several other
cysteine proteases like caspase [50], separase [51] and variants of
cathepsins [38,52–54] are reported to execute proteolytic activity in
this subcellular compartment. Furthermore, DNA has been demon-
strated to act as a template for cathepsins and their inhibitors, and
regulate the proteolytic activity [46]. In the present study nuclear
localization was confirmed for cathepsin L in both HCT116 and
SW620 cells, but less prominent in the SW620 cells, although nuclear
active legumain was found in both cell lines. We have recently
reported the nuclear localization of the endogenous legumain
inhibitor cystatin E/M [55]. Nuclear forms of cathepsin L has
previously been reported to be involved in proteolytic processing of
transcription factors [52,53] and regulation of histone H3 during
mouse embryonic stem cell differentiation [38]. However, evidence
for nuclear localized legumain and the possibility of histone H3.1 as a
potential legumain substrate has not previously been described. The
cysteine proteases are known to interplay during the protease
maturation process, and legumain has been shown to be involved in
processing of cathepsin L [56]. Thus, speculations could be made
towards reciprocal involvement, or redundancy, of legumain and
cathepsin L forms in their biological functions in the cell nucleus.
Interestingly, legumain was recently reported to proteolytically
process the nuclear protein SET [57] and TDP-43 [58], but the
exact subcellular location of this process remained elusive.
In recent years, research on legumain has gained momentum,
reflecting the significance in cancer progression and potential as a
therapeutic target. However, knowledge about subcellular local-
ization, requirements for activation and proteolytic activity
remained largely unexplored as of now. This study demonstrated
that legumain maturation is not identical in all CRC cells, and this
is probably due to factors other than alterations of the amino acid
chain of the protein per se, possibly intracellular trafficking or
absent cleavage by other proteases. Most importantly, the study is
the first to address legumain expression and proteolytic activity in
the nucleus of CRC cells. Histone H3.1 was demonstrated to be a
potential legumain substrate, but the in vivo functional implications
of legumain activity in the nucleus are yet to be explored. The
presented data enhance our knowledge on legumain biology, but
further studies are warranted to elucidate the contribution of
legumain processing and localization in cancer development and
progression.
Supporting Information
Figure S1 Down-regulation of legumain with siRNA
demonstrated specificity of the utilized antibody. Sub-
confluent cultures were transfected with 10 nM siRNA specific for
legumain (Ambion) or Select Negative Control 2 (Ambion) using
Lipofectamine (Invitrogen) and Opti-MEM I (Invitrogen). After
24 h the growth medium was changed and cells grown for an
additional 48 h before harvesting. Immunoblot stained with the
legumain antibody demonstrated that both the 56 pro- and
36 kDa mature form of legumain are down-regulated in siRNA-
treated cells. a-tubulin was used as loading control.
(TIF)
Figure S2 Uncut immunoblots from figure 1, 2 and 7,
and additional subcellular enrichment. (A) Uncut immu-
noblots of legumain (upper panel) and cathepsin L (lower panel) in
Fig. 1, respectively. The bands detected around 98 kDa forms in
TC7 and SW620 are thought to be a dimeric form of the 56 kDa
prolegumain. (B) Subcellular enrichment using a kit from Qiagen
demonstrating nuclear localized 36 kDa legumain in HCT116
and SW620 cells. Cytosol (C), membranes/lysosomes (M/L) and
nuclei (N). Purity controls of the subcellular fractions were assessed
by staining for the proteins a-tubulin (cytosolic), lamp-2 (lysosom-
al) and Lamin-B (nuclear). (C) Uncut immunoblots of legumain
from subcellular fractions in Fig. 2A (upper panels), and from
subcellular fractions in Fig. 2B legumain (middle panels) and
cathepsin L (lower panels). (D) Uncut immunoblots of legumain
(upper panels) and histone H3.1 (lower panels) in Fig. 7A.
Legumain was immunostained on identical blots after stripping off
anti-histone H3.1 and the respective secondary antibody, thus
some residual signal of intact histone H3.1 at 17 kDa remained.
(TIF)
Figure S3 Negative controls for legumain immunofluo-
rescence, immunohistochemistry and in situ activity,
and H/E staining of subcutaneous xenografts. (A and B)
HCT116 and SW620 cells, respectively, incubated without
primary legumain antibody and stained with Alexa488 labeled
rabbit-anti-goat antibody and nuclei stained with DRAQ5TM.
Scale bars represent 10 mm. (C and D) Hematoxilin/Eosin
staining of subcutaneus xenografts from HCT116 and SW620
cells, respectively. Scale bars represent 50 mm. (E and F) Goat-IgG
isotype control staining of subcutaneus xenografts from HCT116
and SW620 cells, respectively. A very faint, diffuse background
staining was observed in tumor cells, while this was more
pronounced in certain areas, possibly necrotic tissue. Scale bar
represents 50 mm. (G) Goat-IgG isotype control staining of human
colorectal tumor tissue. Scale bar represents 50 mm. (H and I)
HCT116 cells incubated with buffers for in situ legumain activity
without presence of the cleavable substrate (H) and with substrate
and 100 nM recombinant cystatin E/M (I). Scale bars represent
10 mm. (J) Subcutaneous xenografts from SW620 cells incubated
with and without substrate, and with substrate and E64 or cystatin
E/M. Scale bar represents 200 mm.
(TIF)
Figure S4 Predicted NLS in legumain. The FASTA
sequence of legumain (Q99538) was analyzed for potential NLS
signals using NLS-mapper. The return score for monopartite
(aa284–293) and bipartite signals (aa313–342) of 6 and 5.1,
respectively, indicated a moderately strong, but not exclusive,
nuclear localization signal in the protein.
(TIF)
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